Jim Cramer on what is driving Eli Lilly's stock right now

Key Concepts

• Eli Lilly (LLY): Pharmaceutical company, stock performance driven by clinical trial data (GOP ONE).
• Alphabet (GOOGL): Parent company of Google, YouTube, Waymo; perceived as undervalued but demonstrating strong performance across multiple ventures.
• McKesson (MCK): Pharmaceutical distributor; identified as potentially over-profiting with minimal contribution, historically experiences stock increases upon earnings reports.
• Amazon (AMZN): E-commerce and cloud computing giant; stock volatility and sensitivity to seller activity post-earnings.
• Magnificent Seven: Group of large-cap technology stocks (Alphabet is included).
• Gemini: Google’s chatbot, considered a leading competitor.
• Waymo: Alphabet’s self-driving car technology.

---

Eli Lilly & Upcoming Data Release

The speaker highlights that Eli Lilly’s (LLY) recent stock performance isn’t solely attributable to earnings reports. Instead, the primary driver is anticipation surrounding new data releases from the GOP ONE clinical trials. The implication is that positive data could significantly boost the stock price after the close of trading. No specific details regarding the GOP ONE trial are provided, but it’s presented as a key catalyst for potential gains.

Alphabet: The “Coolest” of the Magnificent Seven

Alphabet (GOOGL) is positioned as a particularly strong investment. The speaker acknowledges that many analysts previously considered it the weakest link within the “Magnificent Seven” – a group of high-performing technology stocks – due to concerns about Google’s Gemini chatbot. However, the speaker argues that Gemini has proven successful, becoming one of the best chatbots available. Beyond Gemini, the speaker emphasizes the strength of Alphabet’s diverse portfolio, including YouTube (described as the “most popular video site in the world”) and Waymo (self-driving cars). The speaker’s personal investment in Alphabet, including repurchasing shares for a charitable trust due to “seller’s remorse,” underscores their conviction in the company’s potential. They predict a strong performance when Alphabet reports earnings, stating “I think you could romp.”

McKesson: The “Drug Middleman” & Earnings Pattern

A “wild card” prediction focuses on McKesson (MCK), a pharmaceutical distributor. The speaker describes a consensus view within the healthcare industry – among doctors, drug executives, and health insurers – that drug distributors are the most profitable entities with the least contribution to the healthcare system. McKesson is specifically alluded to as the primary example, with the speaker noting a non-verbal acknowledgement (“they don’t say a thing, but they wink”) when McKesson is mentioned in these discussions. Historically, McKesson’s stock price has increased upon earnings reports, and the speaker bets that this pattern will repeat on Thursday evening. This suggests a belief that the market undervalues McKesson’s earnings potential or that the company consistently delivers positive surprises.

Amazon: A Volatile Battleground

Amazon (AMZN) is characterized as a “battleground” stock, exhibiting significant volatility around earnings releases. The speaker contrasts Amazon’s past performance, where earnings reports consistently drove stock increases, with its current behavior. Now, the stock tends to decline after initial gains as sellers capitalize on the increase. Conversely, if Amazon’s stock price falls on the opening, it tends to continue declining. The speaker notes that positive aspects of Amazon’s business are “lost in the shuffle” due to this volatility.

Logical Connections & Synthesis

The speaker connects these individual stock analyses through the overarching theme of identifying potential investment opportunities based on upcoming earnings reports and specific catalysts. The analysis moves from companies with clear positive catalysts (Eli Lilly, Alphabet, McKesson) to one with more uncertain prospects (Amazon). The speaker’s personal anecdotes (seller’s remorse with Alphabet) and industry insights (the perception of McKesson) add credibility and context to the predictions.

The main takeaway is a focus on identifying companies poised for significant movement based on upcoming news and understanding the specific dynamics influencing their stock performance. The speaker emphasizes the importance of looking beyond simple earnings reports and considering factors like clinical trial data, competitive positioning, and industry perceptions.